Non-glycoside, non-catecholamine inotropic agents in the treatment of congestive heart failure.
D000284:Administration, Oral; D000631:Aminopyridines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D000676:Amrinone; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D002118:Calcium / Q000378:metabolism; D002302:Cardiac Output; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000242:Cyclic AMP / Q000037:antagonists & inhibitors; D004305:Dose-Response Relationship, Drug; D017335:Enoximone; D006333:Heart Failure / Q000188:drug therapy*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D007275:Injections, Intravenous; D020105:Milrinone; D005082:Physical Exertion; D011728:Pyridones / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced; D013997:Time Factors
D000631:Aminopyridines; D002316:Cardiotonic Agents; D007093:Imidazoles; D011728:Pyridones; D017335:Enoximone; D000242:Cyclic AMP; C029758:sulmazole; D020105:Milrinone; D000676:Amrinone; D002118:Calcium